EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY
References (29)
- et al.
Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells: Identification as granulocyte colony-stimulating factor (G-CSF)
J Biol Chem
(1983) - et al.
Purification of hemopoietic progenitor cells from human marrow using a fucose binding lectin and cell sorting
Blood
(1980) - et al.
Demonstration of granulocytopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue
Blood
(1977) - et al.
Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF)
Biochem Biophys Res Comm
(1987) - et al.
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma Blood
(1986) Principles of chemotherapy in cancer
- et al.
Autologous bone marrow transplantation: present status and future prospects
Aust NZ J Med
(1987) - et al.
Bacterial infections in neutropenic patients in supportive care
The molecular biology and function of the granulocyte-macrophage colony stimulating factors
Blood
(1986)
Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells
Int J Cancer
Granulocyte colony-stimulating factor and differentiation-induction in myeloid leukemic cells
Int J Cell Cloning
Identification of the human analogue of a regulator that induces differentiation in murine leukaemic cells
Nature
Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors
Blood
Cited by (637)
Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients
2018, European Journal of CancerCitation Excerpt :Current treatment guidelines from the American Society of Clinical Oncology [1], the National Comprehensive Cancer Network [2], the European Organisation for Research and Treatment of Cancer [3], the European Society for Medical Oncology [4] and Canadian supportive care guidelines [5] recommend the prophylactic use of granulocyte colony–stimulating factors (G-CSFs) in patients receiving chemotherapy when the risk of FN is ≥ 20%, and in patients with FN risk between 10–20% who have additional risk factors such as age ≥65 years, poor performance status and prior FN. In clinical trials and daily practice, primary and secondary prophylaxis with G-CSF has been shown to reduce FN incidence, its complications and improve outcomes of cancer treatment [6–11]. The G-CSF class of therapeutic agents was developed by isolating, purifying, and cloning this haematopoietic regulatory factor [12].
Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
2023, CPT: Pharmacometrics and Systems Pharmacology